CX3CR1 and Hepatic fibrosis: Thirdly, the authors proposed targeting Cx3cr1+Ccr2+MyD88+ Mo-macs-mediated liver fibrosis, which showed improvement upon treatment with the MyD88 inhibitor, ST2825, in Mettl14-KO mice.